Contact this trialFirst, we need to learn more about you.
BTK Inhibitor
Rilzabrutinib for Immune Thrombocytopenia
Recruiting1 awardPhase 2
Toronto, Ontario
This trial is testing a new drug, PRN1008, for people with ITP who have tried other treatments that haven't worked. The dosage is still being determined, but right now it's 400 mg twice daily.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service